Author:
STEENS A.,VESTRHEIM D. F.,AABERGE I. S.,WIKLUND B. S.,STORSAETER J.,RIISE BERGSAKER M. A.,RØNNING K.,FURUSETH E.
Abstract
SUMMARYFor decades, vaccination with the 23-valent polysaccharide pneumococcal vaccine (PPV23) has been available for risk groups aged ⩾2 years to prevent invasive pneumococcal disease (IPD). Recently, a 13-valent pneumococcal conjugated vaccine (PCV13) has been licensed for use in all age groups. PCV13 may induce better protection than PPV23 because of different immunogenic properties. This called for a revision of vaccine recommendations for risk groups. We therefore reviewed literature on risk groups for IPD, and effectiveness and safety of pneumococcal vaccines and supplemented that with information from public health institutes, expert consultations and data on IPD epidemiology. We included 187 articles. We discuss the implications of the heterogenic vulnerability for IPD within and between risk groups, large indirect effects of childhood immunization, and limited knowledge on additional clinical benefits of PCV13 in combination with PPV23 for the Norwegian recommendations. These are now step-wise and consider the need for vaccination, choice of pneumococcal vaccines, and re-vaccination interval by risk group.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Epidemiology
Reference96 articles.
1. Cigarette Smoking and Invasive Pneumococcal Disease
2. Norwegian Institute of Public Health (http://www.msis.no/). Accessed 23 September 2011.
3. Merck & Co. Inc. Pneumovax® 23 (pneumococcal vaccine polyvalent) (http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf). 2013.
4. Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma
5. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease;Mahmoodi;European Cytokine Network,2009
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献